DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters

Andreas Stallmach,Bernd Bokemeyer,Jeffrey L. Axler,R. Curtis,Robert Ehehalt,B. Feagan,Parnia Geransar,A. James,Arpeat Kaviya,Javaria Mona Khalid,Douglas C. Wolf,Stefan Schreiber

Journal of Crohns & Colitis（2017）

引用 1|浏览11

暂无评分

摘要

Background: Sustained remission is a key therapeutic goal in ulcerative colitis (UC). Vedolizumab (VDZ) was more effective than placebo as induction and maintenance therapy in patients (pts) with moderately to severely active UC in the GEMINI 1 study (NCT00783718). This post hoc analysis assessed su

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要